Alembic Pharmaceuticals Ltd receives EIR for its Oncology Injectable Formulation Facility at Panelav

Alembic Pharmaceuticals Ltd has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our Oncology Injectable Formulation Facility at Panelav during the period from 4th October, 2022 to 14th October, 2022. This was preapproval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA. The Company had also started receiving ANDA approval manufactured at this facility.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 599.20 as compared to the previous close of Rs. 588.10. The total number of shares traded during the day was 2937 in over 339 trades.

The stock hit an intraday high of Rs. 601.00 and intraday low of 590.25. The net turnover during the day was Rs. 1752757.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 EIR USFDA Oncology InjectableFormulationFaciity Panelav